UNSPSC 51172418: Amylase/cellulase/hyoscyamine/lipase/phenyltoloxamine/protease

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.

UNSPSC 51172418 Amylase/cellulase/hyoscyamine/lipase/phenyltoloxamine/protease is a Commodity code under which state and local governments procure drug-screening reagents and testing consumables for criminal justice and community supervision applications. The recent activity shows county corrections departments soliciting immunoassay screening supplies and confirmation testing materials (LC/MS/MS or GC/MS methodologies) to support specimen collection operations, drug panel analysis, and alternative testing modalities including oral fluid and hair testing. Work includes supplying consumables and reagent kits to support multi-panel drug screening (five-panel and six-panel configurations) with the vendor responsible for maintaining SAMHSA, state DPS, or CAP lab certification and delivering results within contracted service-level parameters.

Collin County Community Supervision and Corrections Department in Texas represents the clearest recent buyer under this code, having issued RFP 2026-327 on September 25, 2026 for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewals. The scope encompasses approximately 25,031 annual tests across multiple screening and confirmation methodologies, staffing of collection sites in Plano and McKinney, and electronic result reporting. The county evaluates proposals on vendor understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points), with optional demonstrations and interviews worth up to 30 points. Pricing must be submitted on a per-test basis under three service models (screening only, confirmation after screening, or screening with automatic confirmation of positives), with all costs including freight, delivery, insurance, and staffing, and price reductions required if the vendor offers lower rates elsewhere. No additional surcharges are permitted, and price redetermination is limited to annual anniversaries based on medical CPI increases not exceeding 3.0 percent.